Sentiment Trading

Caribou Biosciences Inc. is at a critical juncture, with its innovative CRISPR technology holding promise but its financial metrics and market performance raising concerns about its ability to sustain growth.

Caribou Biosciences, a CRISPR genome-editing company, will participate in the BofA Securities 2025 Health Care Conference, highlighting its commitment to advancing its pipeline and engaging with investors.